All clinical trials

The ABATE trial is studying the effects of a study vaccine named ACI-24.060 in people with early Alzheimer’s disease. A build-up of protein Abeta (Aβ) in the brain is believed […]

Dementia and Cognition

Open for Recruitment

Part II of the ABATE Study explores the effect of a new vaccine called ACI-24.060 on people with Down’s syndrome. People with Down’s syndrome have an increased risk of developing […]

Dementia and Cognition

ABHACUS: A Brain Health study: Assessing Cognition Using digital appS

This study aims to understand if a smartphone app can be used to collect information about memory and cognitive health. During the study, people with and without mental and neurological […]

Digital Intervention

Open for recruitment

The purpose of this research study is to compare the effects of ALTO-100, the study’s investigational drug, versus placebo (an inactive substance) in treating symptoms of depression in participants who […]

AROMAPT-SC-1001

Scientists know that two proteins—amyloid beta (Aβ) and tau—build up in the brains of people with Alzheimer’s disease (AD). When tau accumulates abnormally, it forms tangles inside brain cells, which […]

Dementia and Cognition

Open for recruitment

There are currently limited treatment options available for people experiencing depressive symptoms. Very little is known about using antidepressants in patients living with bipolar. Antidepressants can be very effective in […]

Open for recruitment

BHC (Brain Health Clinic)

The Oxford Brain Heath Clinic (BHC) is a new integrated research and clinical environment. It is dedicated to preparing clinical services for the 21st century to preserve brain health. The […]

Dementia and Cognition

Many people who receive antidepressant treatment for their depression do not get an adequate response to these treatments. This sometimes refer to as treatment-resistant depression or TRD. This study will […]

CVHB937A12201 Study (Novartis)

The CVHB937A12201 Study is looking to find out more about an investigational medication (called a study drug) in people with mild AD. We want to look at the study drug […]

Dementia and Cognition

We are currently recruiting for the DNA, Children + Young People’s Health Resource (D-CYPHR), a study open to families with children aged 0 to 15 years. Most diseases start in […]

NIHR BioResource

Open for recruitment

DFP: Deep and Frequent Phenotyping: Combinatorial Biomarkers for Dementia Experimental Medicine

The DFP study aims to create a database of different measures taken by people at risk of Alzheimer’s disease. The measures include regular brain scans, cognitive and memory tests, scans […]

Dementia and Cognition

The Genetic Links to Anxiety and Depression (GLAD) Study is a project set up to support studies exploring risk factors for depression and/or anxiety. We are looking for people with lived […]

NIHR BioResource

Open for recruitment

ISAP: Impact of Semaglutide in Amyloid Positivity: The ISAP Proof of Concept Study

The ISAP Study led in collaboration between the Diabetes Trial Unit and the Department of Psychiatry at the University of Oxford and Novo Nordisk will examine whether semaglutide, a tablet […]

Dementia and Cognition

This is a multi-center, randomized, double-blind, placebo-controlled, inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117570 in adults with a primary diagnosis of schizophrenia who […]

Open for recruitment

PACE-1 (ALTO 207-201)

A Clinical Study for Adults with Depression We are looking for adults between the ages of 18 and 75, currently taking 1 to 2 antidepressants, to take part in a […]

Open for recruitment

RENEW-MDD-1 is a clinical research study for people with major depressive disorder (MDD). To join this study, you must: You will continue taking your current depression treatment. This study will […]

Open for recruitment

Alzheimer’s disease begins long before symptoms show. The ReTain study is evaluating whether an investigational medication is safe, tolerable and effective at slowing the onset of Alzheimer’s disease symptoms for […]

Dementia and Cognition

A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis.

SMILE BioResource

We’re excited to be leading the SMILE BioResource, launching late 2025, in collaboration with the University of Oxford. The SMILE BioResource will support vital research into the causes, diagnosis, and treatment […]

NIHR BioResource

Study of MK-2214 in Participants with Early Alzheimer’s Disease

This trial is testing an investigational medication in people who have early Alzheimer’s disease. Researchers want to learn about the safety of the investigational medication and how well it may […]

Dementia and Cognition